^
    2d
    CLIN1601 PCM204t: Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Steba Biotech S.A. | Trial completion date: Nov 2024 --> Feb 2025
    Trial completion date • HEOR
    |
    Tookad (padeliporfin)
    7d
    Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    2ms
    Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer (clinicaltrials.gov)
    P1, N=36, Recruiting, Impact Biotech Ltd | Suspended --> Recruiting
    Enrollment open
    |
    Tookad (padeliporfin)
    3ms
    Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer (clinicaltrials.gov)
    P1, N=36, Suspended, Impact Biotech Ltd | Trial completion date: Dec 2027 --> Dec 2028 | Not yet recruiting --> Suspended | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial suspension • Trial primary completion date
    |
    Tookad (padeliporfin)
    4ms
    Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Impact Biotech Ltd | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Tookad (padeliporfin)
    7ms
    Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Impact Biotech Ltd | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tookad (padeliporfin)
    9ms
    UCM301: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov)
    P3, N=100, Recruiting, Steba Biotech S.A. | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial primary completion date
    |
    Tookad (padeliporfin)
    10ms
    Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Impact Biotech Ltd | Trial completion date: Dec 2026 --> Dec 2027 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Mar 2025 --> May 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Tookad (padeliporfin)
    10ms
    Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Impact Biotech Ltd | Trial completion date: Oct 2025 --> Oct 2026 | Initiation date: Oct 2023 --> Apr 2024 | Trial primary completion date: Oct 2024 --> Apr 2025
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    Tookad (padeliporfin)
    1year
    Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Completed --> Active, not recruiting | Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    over1year
    Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Steba Biotech S.A.
    New P1 trial
    |
    Tookad (padeliporfin)
    over1year
    Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Steba Biotech S.A.
    New P1 trial • Metastases
    |
    Tookad (padeliporfin)
    over1year
    A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Completed --> Active, not recruiting | Trial completion date: Feb 2023 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Feb 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    3years
    Investigating the multi-modality anti-tumour effects of combined sequential tumour irradiation and vascular-targeted photodynamic therapy in preclinical prostate cancer. (NCRI 2021)
    We investigated whether sequential delivery of 3x5 Gy FRT followed by VTP (at 7-9 mg/kg WST-11) 7 days later improved tumour control compared to monotherapy with FRT or VTP alone...Further research aims to identify potential mechanisms of co-operation between these two treatments, with the aim of harnessing anti-tumour immunological responses. Impact statement This pre-clinical data provides first proof-of-concept for this multi-modality treatment, and may help to inform the design of future early phase clinical trials.
    Preclinical
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1)
    |
    Tookad (padeliporfin)
    over3years
    [VIRTUAL] Intermittent WST-11 Vascular Target Photodynamic Therapy in a Mouse Orthotopic Bladder Model (AUA 2021)
    A mouse orthotopic bladder urothelial model via injection of MB-49 cell line is feasible and displays a very high tumor take rates. Intermittent VTP treatment has an effect on mouse bladder tumors as shown by the decrease in tumor size, weight and change in histology. Additional refinement to the model may provide a means to establish an appropriate timeline and utility for future studies.
    Preclinical
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1)
    |
    CD31 expression
    |
    Tookad (padeliporfin)